{'fraction_non_alphanumeric': 0.02531645569620253, 'fraction_numerical': 0.004219409282700422, 'mean_word_length': 5.700564971751413, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
PROTON PUMP INHIBITORS FOR FUNCTIONAL DYSPEPSIA

Functional dyspepsia (FD) has traditionally been described as chronically occurring epigastric pain for which no specific cause can be identified. In addition, upper abdominal bloating, burping, and/or early satiety are often present. Although a normal upper endoscopy rules out disease process, it has not been beneficial in guiding symptom management. More recently, FD has been included in a group of disorders now called disorders of gut–brain interaction. The Rome Classification is a set of criteria used to describe the pathophysiology, symptoms, and treatment recommendations for these disorders. The Rome IV algorithms are the most current and suggest that dyspepsia may be concurrent with gastroesophageal reflux disease (GERD) (Schmulson, 2018). Because the cause of FD is poorly understood, effective interventions are controversial. Although gastric acid secretion is often normal in patients with FD, treatment has historically focused on medications which at least partially affect acid secretion such as H2 antagonists, anticholinergics, and proton pump inhibitors (PPIs). PROTON PUMP INHIBITORS FOR FUNCTIONAL DYSPEPSIA